Albiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.
Albiruni Ryan Abdul Razak, MRCP, MBBCh
Advertisement
Articles by Albiruni Ryan Abdul Razak, MRCP, MBBCh
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5